FGF2 and Huntington disease: Notably, the new striatal cells recruited after administration of FGF-2 presented phenotypical features of medium-sized spiny neurons (as indicated by DARPP-32 immunolabeling), and this increase in endogenous striatal neurogenesis was accompanied by an improvement of functional outcomes in this animal model of HD (Jin et al., 2005).